

SUBJECT INDEX TO VOLUME 61

- Acoustic startle
modulation of, in rhesus monkeys, 389
- Addiction
alcohol. *See* Alcohol dependence; Alcoholism
high-fat diet, 1019
- ADH4*
substance dependence and, 599
- Adolescents
cannabis use by, 31
obsessive-compulsive disorder in
attention-deficit/hyperactivity disorder and, 316
symptoms of, 285
posttraumatic stress disorder in, 382
prefrontally guided behaviors in, catechol-O-
methyltransferase gene polymorphism variations and,
626
schizotypal, putative biomarkers in, 1179
testosterone and aggression relationship in, cortisol effects
on, 405
- Affective disorders
glycogen synthase kinase-3 regulation in, 139
refractory, cerebrospinal fluid glutamate and glycine levels
in, 162
- Affymetrix chips
single nucleotide polymorphisms on, 13
- African-Americans
nicotine dependence in, 48
- Aggression
atomoxetine-related, in attention-deficit/hyperactivity
disorder patients, 694
genetic risk for, 1100
monoamine oxidase-A gene and, 1100
testosterone and, cortisol effects on relationship between,
405
- Agreeableness, 599
- Alcohol
dopaminergic neurons in ventral tegmental area reduced by
repeated use of, 93
early use of, genetic and environmental predictors of, 1228
self-administration of, corticotropin-releasing factor 1
antagonists effects on, 78
- Alcohol dependence
corticotropin-releasing factor 1 antagonists effects on, 78
families, cerebellar volume in offspring of, 31
naltrexone for, 1290
serotonin 1B receptor and, 974
- Alcohol drinking
buprenorphine-induced reduction in, by NOP receptor
activation, 4
serotonin transporter 5-HTTLPR polymorphism and, 609
- Alcoholism
amygdala activation reductions in adults at risk for, 1306
biological bases of, 1
ethanol seeking behaviors, neural activation associated
with, 979
family history of, 1306
nicotine addiction and, 1
- Amphetamines
dopaminergic neurons in ventral tegmental area reduced by
repeated use of, 93
norepinephrine transporter gene variation modulates acute
response to, 1296
- Amygdala
activation reductions, in adults at risk for alcoholism, 1306
dorsolateral prefrontal cortex responses and, in unipolar
depression, 198
fear memory in, striatal-enriched protein tyrosine
phosphatase effects on, 1049
inhibitory gating of single unit activity in, 880
mGluR2/3 agonist injections into, 591
reactivity of, mood-congruent memory and, 231
serotonin transporter genotype effects on, 1011
volume of
in bipolar disorder, 743
in siblings of autistic individuals, 512
- Anorexia nervosa
correlates of, 348
opioid delta 1 receptor gene polymorphisms and, 367
prevalence of, 348
serotonin 1D receptor gene polymorphisms and, 367
serotonin-1A receptor activity in, 1090
- Anterior cingulate cortex
in methamphetamine abusers, 1272
- Antidepressants
behavioral changes after cessation of use, 991
behavioral models of, 661
brain-derived neurotrophic factor upregulated in
hippocampus by, 661
ceftriaxone effects that mimic, 250
dopamine D2-like receptors and, 145
mesolimbic dopamine system's role in response to, 145
Pd34 isoform targeting by, 56
riluzole and, for residual depressive symptoms, 822
serotonin transporters and, 734
- Anxiety
environmental risk factors for, 1062
rat models of, 782
- Anxiety disorders
bipolar disorder and, comorbidities between, 819
- AP-2
DNA-binding activity, carbamazepine effects on, 154
- AP-2a
protein expression, carbamazepine effects on, 154
- Aripiprazole
cocaine seeking behaviors blocked with, 582
- At risk mental state
regional gray matter volume abnormalities in, 1148
- Atomoxetine, for attention-deficit/hyperactivity disorder
aggression/hostility-related events associated with, 711
continuation treatment using, 694
- Attentional control
in methamphetamine abusers, 1272
- Attention-deficit/hyperactivity disorder
atomoxetine for
aggression/hostility-related events associated with, 711
continuation treatment using, 694
conduct disorder and, 1329
continuation treatment for, after 1 year of age, 694
dexmethylphenidate extended-release capsules for, 1380
disruptive behavior disorders and, 1329
episodic memory in, emotional salience effect on, 1370
mixed amphetamine salts extended release for, 706
neuroanatomical findings in, 1361
neurobiology of, 1317

- obsessive-compulsive disorder and, 316, 1388
- oppositional defiant disorder and, 1329
- response inhibition impairment in, 1395
- reward anticipation in, ventral striatal hypo-responsiveness during, 720
- Strengths and Weaknesses of ADHD-Symptoms and Normal-Behavior Scale, 700
- structural imaging findings in, 1361
- subtypes
 - dimensional analysis of, in rats, 1340
 - prenatal smoking exposure and, 1320
- twin studies of, 700
- working memory impairment in, 1395
- X-monosomy effects on attention and, 1351
- Atypical antipsychotics
 - prefrontal cortex neurons fine-tuned using, 679
 - for treatment-resistant depression, 671
- Auditory cortex
 - in schizophrenia, 829
- Auditory evoked potentials
 - nicotine effects on, 23
- Auditory processing
 - deficient, in speech selectivity in selective mutism, 419
- Autism
 - in children
 - omega-3 fatty acids supplementation in, 551
 - risperidone effects on prolactin levels of, 545
 - cortical dysfunction in, 465
 - diagnostic interview for, 438
 - executive function maturation in, 474
 - genetics of, 429, 438
 - head circumference growth in infants later diagnosed with, 458
 - pharmacological treatment of, 521
 - prepulse inhibition deficits in, 482
 - research of, 427
 - sensorimotor gating deficits in, 482
 - siblings of individuals with, 512
 - social cognition in, oxytocin effects on retention of, 498
- Autism spectrum disorders
 - cortical layering and thickness in, 449
 - gastrointestinal symptoms in children with, dietary intake relationship to, 492
 - phenotypic homogeneity in, 438
 - placental trophoblast inclusions in, 487
- Behaviors
 - Group A streptococcus infections and, relationship between, 279
- Benzodiazepines
 - before single-photon emission computed tomography, 422–corr
- Binge eating disorder associated with obesity
 - topiramate for, 1039
- Bipolar affective disorder
 - chromosome 4p locus linked to, 797
 - schizophrenia and, 797
 - tryptophan hydroxylase variations and, 181
- Bipolar disorder
 - amygdala volume deficits in, 743
 - anxiety disorders and, comorbidities between, 819
 - cerebral white matter in, 743
 - in children, 819
 - depression and, regional cerebral glucose metabolic abnormalities in, 765
 - entorhinal cortex in, 640
 - first-episode
 - amygdala volume deficits in, 743
 - structural changes in, voxel-based study of, 776
 - manic episodes in, plasma brain derived neurotrophic factor levels and, 142
 - occipital cortex t-aminobutyric acid in, 806
 - parvalbumin neurons in entorhinal cortex of patients diagnosed with, 640
 - suicide attempts and, 725
 - 2p12 and, 725
- Brain-derived neurotrophic factor
 - conditional knockout models, depression-related behaviors in, 187
 - depression and, 187, 1112–corr
 - hippocampal upregulation of, antidepressant effects on, 661
 - in obsessive-compulsive disorder, 322
 - plasma levels, in bipolar patients during manic episodes, 142
 - serotonin transporter and, 1112–corr
 - Val66Met, 911
- Bulimia nervosa
 - correlates of, 348
 - prevalence of, 348
- Buprenorphine
 - alcohol drinking reduced using, 4
 - duration of action, 101
 - at mu-opioid receptors, 101
 - NOP receptor activation by, 4
 - opioid dependence treated with, 101
 - pharmacokinetics and pharmacodynamics of, 101
- Bupropion
 - tobacco dependence treated with, catechol-O-methyltransferase gene as predictor of response to, 111
- Candidate gene polymorphisms
 - in serotonergic pathways, 223
- Cannabis
 - adolescent use of, 31
 - dorsolateral prefrontal cortex N-acetylaspartate/total creatine loss secondary to recreational use of, 1281
 - prenatal exposure to, heroin-seeking behaviors in adulthood, 554
- CAPON gene, 873
- Carbamazepine
 - AP-2 DNA-binding activity downregulated by, 154
 - AP-2a protein expression affected by, 154
 - membrane G-protein receptor kinase levels affected by, 246
- Catechol-O-methyltransferase
 - bupropion therapy for tobacco dependence and, 111
 - estrogen and, in compulsive behavior, 359
 - polymorphism variations
 - prefrontally guided behaviors in adolescents and, 626
 - schizophrenia and, 1127
 - schizophrenia and, 1127, 1135
 - val158 Met genotype, 845, 1127
- [11C]DASB, 1314–corr
- Ceftriaxone
 - antidepressant-like effects of, in male C57BL/6J mice, 250

- Cerebellar volume
 in obsessive-compulsive disorder, 31
 in offspring of alcohol dependence families, 31
 in trichotillomania, 374
- Cerebral cortex
 layering and thickness of, in autism spectrum disorders, 449
- Cerebral glucose metabolic abnormalities
 in bipolar disorder, 765
- Cerebrospinal fluid
 glutamate and glycine, in refractory affective disorder, 162
- Children
 autistic
 omega-3 fatty acids supplementation in, 551
 risperidone effects on prolactin levels of, 545
 bereaved, hypothalamic-pituitary-adrenal axis dysregulation
 in, 957
 bipolar disorder in, 819
 mania in, adaptive strategies for, 758
 neuropsychological performance in, 947
 obsessive-compulsive disorder in
 attention-deficit/hyperactivity disorder and, 316, 1388
 cognitive behavioral treatment for, 337
 neuropsychological performance in, 947
 symptoms of, 285
 tic disorder effects on pharmacologic treatment for, 344
 parental loss effects, 957
 posttraumatic stress disorder in, 382
 stressors experienced by, 957
 Tourette syndrome in, regulatory T cells in, 273
- Children's Global Assessment Scale
 developmental disabilities modification of, 504
- Cholinergics
 REM sleep memory consolidation affected by, 750
- Chromosome 4p locus
 bipolar affective disorder and, 797
- Chromosome 1q23.3 gene UHMK1, 873
- Cigarette craving
 ventral striatal dopamine D1 receptor in, 1252
- Clozapine
 prefrontal cortex neurons fine-tuned using, 679
 schizophrenia treated with, 679
- Cocaine
 craving of, effect of mGluR2/3 agonist injections into
 amygdala on, 591
 dopaminergic neurons in ventral tegmental area reduced by
 repeated use of, 93
 paranoia associated with, dopamine b-hydroxylase gene
 variant inducement of, 1310
 relapse to
 aripiprazole blocks reinstatement of seeking behaviors
 associated with, 582
 mGluR2/3 agonist injections into amygdala for, 591
- Cognition
 cannabis effects on, 31
 nicotine effects on, 31
- Cognitive behavioral treatment
 for obsessive-compulsive disorder in children, 337
- Cognitive performance
 schizotypy effects on, 845
- College student drinking
 serotonin transporter 5-HTTLPR polymorphism and, 609
 stressful life events and, 609
- Conduct disorder
 attention-deficit/hyperactivity disorder and, 1329
- Context processing
 abnormalities in schizotypal personality disorder,
 guanfacine effects on, 1157
- Cooperation
 social, in psychopathy, 1260
- Corticotropin-releasing factor 1 antagonists
 alcohol self-administration in alcoholics reduced using, 78
- Cortisol
 in bereaved children, 957
 metyrapone effects on, 952
 testosterone and aggression relationship affected by, 405
- DAO
 as schizophrenia susceptibility locus, 1194
- Decision making
 reward-related, in depression, 633
- Deep brain stimulation
 major depression treated with, 831
 movement disorders treated with, 831
 obsessive-compulsive disorder treated with, 831
 Tourette syndrome treated with, 831
- Depression
 behavioral models of, MAP kinase signaling in, 661
 bipolar disorder and, regional cerebral glucose metabolic
 abnormalities in, 765
 brain-derived neurotrophic factor and, 187, 1112–corr
 dorsolateral prefrontal cortex and amygdala responses in,
 198
 in elderly, 223
 environmental risk factors for, 1062
 geriatric, Stroop performance predicted by white-matter
 integrity, 1007
 glutamatergic dysfunction in, 137
 melanin-concentrating hormone receptor 1 antagonism for,
 174
 metabotropic glutamate receptor antagonists for, 17
 murine models of, melanin-concentrating hormone receptor
 1 involvement in, 174
 neural circuitry of, 729
 nicotine dependence and, comorbidity between, 70
 relapse of, amygdala reactivity and mood-congruent
 memory in individuals at risk for, 231
 reward-related decision making alterations in, 633
 riluzole for residual symptoms in antidepressant-treated
 patients, 822
 serotonin transporters and, 1112–corr
 treatment-resistant, atypical antipsychotics for, 671
 unipolar
 amygdala and dorsolateral prefrontal cortex responses
 in, 198
 occipital cortex t-aminobutyric acid in, 806
- Developmental disabilities modification of Children's Global
 Assessment Scale, 504
- Dexmethylphenidate extended-release capsules
 attention-deficit/hyperactivity disorder treated with, 1380
- Diet
 gastrointestinal symptoms in children with autism spectrum
 disorders and, 492
- Dietary preference
 decreases in, emotionality and dietary relapse risks
 secondary to, 1021

- Disgust
 facial expressions of, obsessive-compulsive disorder washing symptoms effect on neural responses to, 1072
- Disrupted in Schizophrenia 1 gene, 1208
- Disruptive behavior disorders
 attention-deficit/hyperactivity disorder and, 1329
- Dissociative disorders
 hypothalamic-pituitary-adrenal axis function in, 966
- Dopamine b-hydroxylase gene
 paranoia during cocaine self-administration influenced by, 1310
- Dopamine D1 receptor
 ventral striatal, in cigarette craving, 1252
- Dopamine D2-like receptors
 antidepressant response and, 145
- Dopamine transporters
 in striatum, minocycline effects on, 577
- Dopaminergic neurons
 methamphetamine-induced death of, in mouse olfactory bulb, 1235
 in ventral tegmental area, long-term stimulant or ethanol use effects on, 93
- Dorsolateral prefrontal cortex
 amygdala responses and, in unipolar depression, 198
 N-acetylaspartate/total creatine loss in, secondary to cannabis use, 1281
- Drug seeking behaviors
 aripiprazole-induced blocking of, 582
 mGluR2/3 agonist injections into amygdala, 591
 neural activation associated with, 979
- Duloxetine
 norepinephrine transporter binding sites affected by, 210
 serotonin transporter binding sites affected by, 210
- Dyskinesia
 levodopa-induced, 836
- Early parental separation
 oxytocin sensitivity in adult men with, 1109
- Eating disorders
 brain-derived neurotrophic factor Val66Met and, 911
 correlates of, 348
 prevalence of, 348
 serotonin 1D receptor gene polymorphisms and, 367
- Elderly
 depression in, 223, 1007
- Emotion
 facial expressions of, 253
- Emotionality
 dietary preference decreases and, 1021
- Entorhinal cortex
 parvalbumin neurons in, in schizophrenia or bipolar disorder patients, 640
- Episodic memory
 in attention-deficit/hyperactivity disorder, emotional salience effect on, 1370
- Escitalopram
 behavioral changes after cessation of use, 991
 norepinephrine inhibition by, risperidone effects on, 671
- Estrogen
 catechol-O-methyltransferase gene and, in compulsive behavior, 359
- Executive function
 maturation of, in autism, 474
 in older adults, 1007
- Extraversion, 599
- Facial expressions of disgust
 obsessive-compulsive disorder washing symptoms effect on neural responses to, 1072
- Fear memory
 striatal-enriched protein tyrosine phosphatase effects on, 1049
- Fear provocation
 substance P neurokinin-1 receptor system affected by, 1002
- Fear-evoking stimuli
 nonconscious processing of, 996
- Fear-potentiated startle
 pharmacological modulation of, in rhesus monkeys, 389
- Feedforward auditory processing
 in schizophrenia, 854
- Frontal cortex
 AP-2 DNA-binding activity and AP-2a protein expression in, 154
- Frontonasal dysmorphology
 in schizophrenia, 1187
- Frontostriatal-limbic pathways, 1007
- Functional magnetic resonance imaging
 striatal function in generalized social phobia studied using, 396
- GABRB2*
 schizophrenia and, 653
- Gamma-aminobutyric acid
 occipital cortex, in recovered unipolar depression and bipolar subjects, 806
- Gastrointestinal symptoms
 in children with autism spectrum disorders, dietary intake relationship to, 492
- Gaze fixation
 in siblings of autistic individuals, 512
- Gene expression
 serotonin 2A receptor gene polymorphisms and, 167
 small interfering RNA effects on, 65
- Gene expression microarrays, 13
- Generalized social phobia
 striatal function in, 396
- Genetic association studies, 1121
- Glial cell line-derived neurotrophic factor
 inducer for, methamphetamine-induced rewarding effects protected by, 890
- Globus pallidus internalis
 in L-3,4-dihydroxyphenylalanine-induced dyskinesia, 836
- Glutamate
 cerebrospinal fluid, in refractory affective disorder, 162
- Glutamatergic dysfunction
 in depression, 137
- Glycine
 cerebrospinal fluid, in refractory affective disorder, 162
- Glycogen synthase kinase-3
 alterations of, in depressed suicide victims, 240
 regulation of, in affective disorders, 139
- Glycogen synthase kinase-3b
 lithium regulation of, in peripheral blood mononuclear cells, 216

- G-protein receptor kinases
mood stabilizers' effect on, in rat frontal cortex, 246
- Gray matter
in autism, 465
regional volume abnormalities, in at risk mental state individuals, 1148
- Group A streptococcus infections
movements and behaviors and, relationship between, 279
- Guanfacine
schizotypal personality disorder context processing abnormalities affected by, 1157
- Haloperidol
clozapine comparisons with, 679
inhibitory gating of single unit activity in amygdala by, 880
- Head circumference growth
autism and, 458
- Heroin use
mu-opioid receptor gene polymorphisms and, 1244
- High anxiety-related behavior rats, 782
- High-fat diet
addiction and, 1019
emotionality and, 1021
- Hippocampus
brain-derived neurotrophic factor upregulation into, antidepressant effects on, 661
glutamate concentration, in schizophrenia, 1218–corr
muscarinic M4 receptor expression, in schizophrenia, 1161
in obsessive-compulsive disorder, 330
volume, intrapair differences in monozygotic twins discordant for anxiety and depression risk, 1062
- 5-HT2A receptor gene
polymorphisms, gene expression influenced by, 167
- Huntington's disease
obsessive and compulsive symptoms in, 415
- Hyperactivity
in pervasive developmental disorders, methylphenidate for, 538
- Hypothalamic-pituitary-adrenal axis
in dissociative disorders, 966
dysregulation in, in bereaved children, 957
metyrapone effects on, 952
in posttraumatic stress disorder, 966
- Hypothalamus
schizophrenia-related abnormalities in, 935
- Imipramine, 991
- Immune tolerance
in Tourette syndrome, 273
- Inhibitory gating of single unit activity in amygdala, 880
- Ketamine
inhibitory gating of single unit activity in amygdala by, 880
- L-3,4-dihydroxyphenylalanine-induced dyskinesia, 836
- Learning
posttraumatic stress disorder and, 382
- Levodopa
dyskinesia induced by, 836
- Limbic system, 813
- Lithium
glycogen synthase kinase-3 β regulation in peripheral blood mononuclear cells by, 216
membrane G-protein receptor kinase levels affected by, 246
- Locomotor arousal
interaction of stress and nicotine-associated cues, 127
- Long-term potentiation
striatal-enriched protein tyrosine phosphatase effects on, 1049
LY379268, 591
- Major depression
deep brain stimulation for, 831
glycogen synthase kinase-3 alterations and, 240
protein kinase B levels and, 240
- Mania
in bipolar disorder, plasma brain derived neurotrophic factor levels and, 142
childhood, adaptive strategies for, 758
- MAP kinase signaling
in behavioral models of depression, 661
- Medial prefrontal hyperactivity
reality distortion and, 1171
- Melanin-concentrating hormone receptor 1
in murine models of depression, 174
- Memory consolidation
REM sleep and, 750
- Memory deficits
posttraumatic stress disorder and, 382
- Mesolimbic dopamine system
antidepressant response and, 145
- Metabotropic glutamate receptor antagonists
depression treated with, 17
nicotine dependence treated with, 17
- Methamphetamine
attentional control in abusers of, 1272
brain metabolite levels in abusers of, 1272
dopaminergic neuron death caused by, in mouse olfactory bulb, 1235
neurotoxicity induced by, minocycline effects on, 577
rewarding effects induced by, 890
- Methylphenidate
inattention and hyperactivity in pervasive developmental disorders treated with, 538
- Metyrapone
hypothalamic-pituitary-adrenal axis affected by, 952
posttraumatic stress disorder-related sleep disturbances treated with, 952
- mGluR2/3 agonists, 591
- Microarrays
gene expression, 13
"Mind-reading"
oxytocin effects on, 731
- Minocycline
dopamine transporters in striatum reduced using, 577
- Mixed amphetamine salts extended release
for attention-deficit/hyperactivity disorder in school-aged children, 706
- MLC1* polymorphisms
periodic catatonia and, 1211
- Monoamine oxidase-A gene
aggression and, 1100
- Mood stabilizers
membrane G-protein receptor kinase levels affected by, 246

- Mood-congruent memory
amygdala reactivity and, 231
- Movement disorders
deep brain stimulation for, 831
- Movements
Group A streptococcus infections and, relationship between, 279
- Mu-opioid receptor
altered binding, after psychological trauma, 1030
buprenorphine at, 101
- Mu-opioid receptor gene polymorphisms
heroin use and, 1244
- Murine models
ceftriaxone studies in, 250
of depression, melanin-concentrating hormone receptor 1 involvement in, 174
X-monosomy effects on visuospatial attention, 1351
- N-acetylaspartate/total creatine level
in dorsolateral prefrontal cortex area, after cannabis use, 1281
- Naltrexone
efficacy testing of, for alcohol dependence treatment, 1290
ethanol seeking behaviors affected by, 979
- NCAM1*
schizophrenia and, 902
- N-Desmethylclozapine
clozapine comparisons with, 679
- Neonatal handling
negative symptoms of schizophrenia, animal models of, 865
- Neurocognition
in schizophrenia, 902
- Neurokinin-1 receptor, 1002
- Neurotrophic tyrosine kinase receptor 2 gene
nicotine dependence and, 48
- Nicotine
inhibitory gating of single unit activity in amygdala by, 880
Pde4b isoform downregulation caused by, 56
- Nicotine addiction
alcoholism and, 1
biological bases of, 1
- Nicotine dependence
in African-Americans, 48
bupropion for, catechol-O-methyltransferase gene as predictor of response of, 111
chromosome 5 risk locus, 119
depression and, 70
in European-Americans, 48
metabotropic glutamate receptor antagonists for, 17
neurotrophic tyrosine kinase receptor 2 gene halotypes with, 48
phosphodiesterase gene expression and, 56
risk loci for, 119
- Nicotine withdrawal
verbal memory deficits during, 31
- NOP receptor
buprenorphine activation of, 4
- Norepinephrine
escitalopram-induced inhibition of, risperidone effects on, 671
- Norepinephrine transporter
binding sites, duloxetine effects on, 210
gene variation, D-amphetamine response modulated by, 1296
- Obesity
binge eating disorder associated with obesity, topiramate for, 1039
dietary relapse and, 1021
- Obsessive-compulsive disorder
in adolescents, 285, 946
attention-deficit/hyperactivity disorder and, 316, 1388
cerebellar volume in, 31
in children
attention-deficit/hyperactivity disorder and, 316, 1388
behavior, 308
cognitive behavioral treatment for, 337
neuropsychological performance in, 947
symptoms of, 285
tic disorder effects on pharmacologic treatment for, 344
cognitive behavioral treatment for, 337
deep brain stimulation for, 831
early-onset, serotonin system candidate genes in, 322
in estrogen deficient male, 359
familial characteristics of, 617
familial risk analysis of, 316
genetic factors in, 308
hippocampal recruitment in, 330
in Huntington's disease, 415
implicit sequence learning in, 330
prenatal, perinatal, and postnatal risk factors in, 301
quetiapine for, 412
research of, 263
rheumatic fever and, 266
risk factors, 301
symptoms of, 285
washing symptoms in, neural responses to facial expressions of disgust modulated by, 1072
Yale–Brown Obsessive Compulsive Scale, 617
- Occipital cortex
gamma-aminobutyric acid, in recovered unipolar depression and bipolar subjects, 806
- Olfactory bulb
dopaminergic neurons in, methamphetamine-induced death of, 1235
- Omega-3 fatty acids
autistic children treated with, 551
- Opioid delta 1 receptor gene polymorphisms
anorexia nervosa and, 367
- Opioid dependence
buprenorphine for, 101
- Oppositional defiant disorder
attention-deficit/hyperactivity disorder and, 1329
- Oxytocin
central sensitivity to, after early parental separation, 1109
“mind-reading” improved using, 731
social cognition retention in autism affected by, 498
- P50, 23, 1204
- Parahippocampal activation
in schizophrenia, 564

- Paranoia
 during cocaine self-administration, dopamine b-hydroxylase gene variant inducement of, 1310
- Paroxetine
 treatment uses of, 782
- Parvalbumin neurons
 in entorhinal cortex of schizophrenia or bipolar disorder patients, 640
- Pde4b
 nicotine effects on, 56
- Periodic catatonia
MLC1 polymorphisms and, 1211
- Peripheral blood mononuclear cells
 glycogen synthase kinase-3 β regulation in, lithium effects on, 216
- Pervasive developmental disorders
 global functioning in children with, 504
 inattention and hyperactivity in, methylphenidate effects on, 538
- Phencyclidine
 neonatal handling effects on, in schizophrenia animal models, 865
- Phosphodiesterase gene expression
 nicotine dependence and, 56
- Placental trophoblast inclusions
 in autism spectrum disorders, 487
- Positron emission tomography
 minocycline effects on dopamine transporters in striatum after methamphetamine abusers, 577
- Posttraumatic stress disorder
 hypothalamic-pituitary-adrenal axis function in, 966
 learning and, 382
 memory deficits and, 382
 mu-opioid receptor binding alterations and, 1030
 nightmares in, 925, 928
 prazosin use in, 925, 928
 sleep disturbances in, 925, 928, 952
- Prazosin
 posttraumatic stress disorder-related sleep disturbances and nightmares treated with, 925, 928
- Prefrontal cortex
 activity-dependent gene expression in, 127
 catechol-O-methyltransferase gene polymorphism variations and, 626
 glutamate concentration, in schizophrenia, 1218–corr
 locomotor arousal, 127
 ventrolateral, in first-episode bipolar disorder, 776
- Prefrontal cortex neurons
 clozapine effects on, 679
- Pregnancy
 cannabis exposure during, 554
- Prenatal smoking
 attention-deficit/hyperactivity disorder subtypes and, 1320
- Preproenkephalin-B-derived opioid transmission
 in striatum, 836
- Prepulse inhibition
 deficits, in autism, 482
 in schizophrenia, 1204
- Prolactin
 risperidone effects on, in children with autism, 545
- Protein kinase B
 major depression and, 240
- Proton magnetic resonance spectroscopic imaging
 cortical dysfunction in autism studied using, 465
- Psychiatric genetics, 1017
- Psychopathy
 social cooperation and non-cooperation as function of, 1260
- Psychosis
Toxoplasma gondii infection and, 1215
- Puberty
 substance disorder risks and, 1223
- Pulvinar nucleus, 813
- Quetiapine
 obsessive-compulsive disorder treated with, 412
- Reality distortion
 medial frontal hyperactivity in, 1171
- Refractory affective disorder
 cerebrospinal fluid glutamate and glycine levels in, 162
- Regional gray matter volume
 in at risk mental state individuals, 1148
- Regulatory T cells
 in Tourette syndrome, 273
- REM sleep
 memory consolidation and, 750
- Response inhibition
 working memory impairment and, in attention-deficit/hyperactivity disorder, 1395
- Reward anticipation
 in attention-deficit/hyperactivity disorder, ventral striatal hypo-responsiveness during, 720
- Reward processing
 alterations of, in depression, 633
- RGS4 gene, 873
- Rheumatic fever
 obsessive-compulsive disorder and, 266
- Risk loci
 for nicotine dependence, 119
- Risperidone
 escitalopram-induced inhibition of norepinephrine reversed by, 671
 prolactin levels in children with autism affected by, 545
- RNA interference
 analysis of gene functions in brain using, 65
- Schizophrenia
 auditory cortex in, 829
 bipolar affective disorder and, 797
 brain-derived neurotrophic factor Val66Met and, 911
 catechol-O-methyltransferase variants and, 1127, 1135
 clozapine for, 679
 cognitive impairments in, 1141
 DAO as susceptibility locus for, 1194
 Disrupted in Schizophrenia 1 genotype and, 1208
 early-onset, *Toxoplasma gondii* as risk factor for, 688
 entorhinal cortex in, 640
 feedforward auditory processing in, impairments in, 854
 frontonasal dysmorphology in, 1187
GABRB2 and, 653
 genetic risk for, 564
 glutamatergic dysfunction in, 162
 hippocampus
 glutamate concentrations, 1218–corr
 muscarinic M4 receptor expression, 1161

- hypothalamic abnormalities in, 935
- NCAM1* and, 902
- negative symptoms of, 865
- neurocognition in, 902
- neurodevelopment, 1119
- p50 suppression in, 1204
- parahippocampal activation alterations, 564
- parvalbumin neurons in entorhinal cortex of patients diagnosed with, 640
- periodic catatonia, *MLC1* polymorphisms associated with, 1211
- phencyclidine-induced behaviors, neonatal handling effects on, 865
- prefrontal glutamate concentration in, 1218–corr
- prepulse inhibition in, 1204
- serine racemase gene variant and, 1200
- siblings of individuals with, level-of-processing effects in, 1141
- smoking in patients with, 23
- susceptibility genes
 - DAO, 1194
 - description of, 873, 1119
- synaptophysin-immunoreactive puncta in, 854
- Toxoplasma gondii* and, 688
- 22q11 deletion syndrome, 1135
- verbal encoding in, 564
- Schizotypal personality disorder
 - context processing abnormalities in, guanfacine effects on, 1157
 - minor physical anomalies in adolescents with, 1179
- Schizotypy
 - catechol-O-methyltransferase val158 Met genotype and, 845
- Selective mutism
 - deficient auditory processing in speech selectivity, 419
- Sensorimotor gating deficits
 - in autism, 482
- Serine racemase gene
 - schizophrenia and, 1200
- Serotonergic pathways
 - candidate gene polymorphisms in, 223
- Serotonin 1A receptor
 - in anorexia nervosa, 1090
 - in social anxiety disorder, 1081
- Serotonin 2A receptor gene
 - polymorphisms, gene expression influenced by, 167
- Serotonin 1B receptor
 - alcohol dependence and, 974
- Serotonin 1D receptor gene polymorphisms
 - anorexia nervosa and, 367
- Serotonin reuptake inhibitors
 - quetiapine addition trials for obsessive-compulsive disorder affected by, 412
- Serotonin system genes
 - in obsessive-compulsive disorder, 322
- Serotonin transporters
 - antidepressant response and, association between, 734
 - binding sites, duloxetine effects on, 210
 - brain-derived neurotrophic factor and, 1112–corr
 - depression and, 1112–corr
 - 5-HTTLPR polymorphism, 609, 813, 1011
- Single nucleotide polymorphisms
 - on Affymetrix chips, 13
- Single-photon emission computed tomography
 - benzodiazepine use before, 422–corr
- Sleep disturbances, posttraumatic stress disorder-related
 - metirapone for, 952
 - prazosin for, 925, 928
- Small interfering RNA
 - knockdown of genes in brain using, 65
- Smoking
 - prenatal, attention-deficit/hyperactivity disorder subtypes and, 1320
 - in schizophrenia patients, 23
 - tryptophan depletion effects, 70
 - ventral striatal dopamine D1 receptor and, 1252
- Social anxiety disorder
 - serotonin-1A receptor binding in, 1081
- Social cognition
 - oxytocin effects on retention of, in autism, 498
- Social phobia
 - striatal function in, 396
- Specific phobia
 - substance P neurokinin-1 receptor system affected by symptom provocation in, 1002
- Startle reflex
 - modulation of, in rhesus monkeys, 389
 - nonconscious processing of fear stimuli and, 996
- Strengths and Weaknesses of ADHD-Symptoms and Normal-Behavior Scale, 700
- Stress
 - cardiovascular responses to, 253
 - childhood, 957
 - facial expressions of emotion as indicators of, 253
 - high-fat diet and, 1021
 - neuroendocrine responses to, 253
 - nicotine-associated cues and, 127
- Stressful life events
 - college student drinking and, 609
- Striatal function
 - in generalized social phobia, 396
- Striatal-enriched protein tyrosine phosphatase
 - long-term potentiation and fear memory affected by, 1049
- Striatum
 - dopamine transporters in, minocycline effects on, 577
 - preproenkephalin-B-derived opioid transmission in, 836
- Substance abuse
 - genetic and environmental predictors of, 1228
- Substance dependence
 - ADH4* variation and, 599
 - personality traits associated with, 599
- Substance disorders
 - brain-derived neurotrophic factor Val66Met and, 911
 - pubertal processes and, 1223
- Substance P neurokinin-1 receptor system, 1002
- Subthalamic nucleus
 - preproenkephalin-B-derived opioid transmission in, 836
- Suicide attempts
 - in bipolar disorder patients, 725
 - tryptophan hydroxylase variations and, 181
 - 2p12 and, 725
- Sumatriptan
 - growth hormone responses to, serotonin 1B receptor diplotypes and, 974
- Synaptophysin-immunoreactive puncta
 - in schizophrenia, 854

- T cells, regulatory
in Tourette syndrome, 273
- Testosterone
aggression and, cortisol effects on relationship between, 405
substance abuse disorder and, 1223
- Tics
in pediatric obsessive-compulsive disorder, 344
sertraline for, 344
in Tourette syndrome, 292
- Topiramate
binge eating disorder associated with obesity treated with, 1039
- Tourette syndrome
deep brain stimulation for, 831
immune tolerance impairments in, 273
regulatory T cells in, 273
tic symptom profiles in patients with, 292
- Toxoplasma gondii*
early-onset schizophrenia and, 688
psychotic symptoms and, 1215
- Trichotillomania
cerebellar volume in, 374
- Tryptophan depletion
depressive symptoms in smokers triggered by, 70
- Tryptophan hydroxylase
bipolar affective disorder and, 181
suicide attempts and, 181
- Tumor necrosis factor- α
inducer for, methamphetamine-induced rewarding effects protected by, 890
- Turner syndrome, 1351
- 22q11 deletion syndrome
catechol-O-methyl transferase and, 1135
- 2p12
suicide attempts in bipolar disorder patients and, 725
- UFP-101, 4
- UHMK1 gene, 873
- Valproate
membrane G-protein receptor kinase levels affected by, 246
- Ventral striatal dopamine D1 receptor
cigarette craving and, 1252
- Ventral tegmental area
dopaminergic neurons in, long-term stimulant or ethanol use effects on, 93
- Ventrolateral prefrontal cortex
in first-episode bipolar disorder, 776
- Verbal encoding
in schizophrenia, 564
- Verbal memory deficits
during nicotine withdrawal, 31
- Visuospatial attention
X-monosomy effects on, in mice, 1351
- Voxel-based morphometry
structural changes in first-episode bipolar disorder studied using, 776
- White matter
in autism, 465
in bipolar disorder, 743
- Working memory impairment
response inhibition and, in attention-deficit/hyperactivity disorder, 1395
- X-monosomy, 1351
- Yale–Brown Obsessive Compulsive Scale, 617